1724 related articles for article (PubMed ID: 16504015)
41. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Besch R; Berking C; Kammerbauer C; Degitz K
Cell Death Differ; 2007 Apr; 14(4):818-29. PubMed ID: 17110957
[TBL] [Abstract][Full Text] [Related]
43. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
44. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
45. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
46. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Albo D; Tuszynski GP
J Surg Res; 2004 Jul; 120(1):21-6. PubMed ID: 15172186
[TBL] [Abstract][Full Text] [Related]
47. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
[TBL] [Abstract][Full Text] [Related]
48. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
49. uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line.
Yoon SY; Lee YJ; Seo JH; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cell Res; 2006 Jan; 16(1):75-81. PubMed ID: 16467878
[TBL] [Abstract][Full Text] [Related]
50. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
51. Role of integrins in invasion of endometrial cancer cell lines.
Prifti S; Zourab Y; Koumouridis A; Bohlmann M; Strowitzki T; Rabe T
Gynecol Oncol; 2002 Jan; 84(1):12-20. PubMed ID: 11748970
[TBL] [Abstract][Full Text] [Related]
52. Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding.
Ramani VC; Haun RS
Pancreas; 2008 Nov; 37(4):399-404. PubMed ID: 18953252
[TBL] [Abstract][Full Text] [Related]
53. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
54. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
55. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA.
He X; Zheng Z; Li J; Ben Q; Liu J; Zhang J; Ji J; Yu B; Chen X; Su L; Zhou L; Liu B; Yuan Y
Carcinogenesis; 2012 Mar; 33(3):555-62. PubMed ID: 22223849
[TBL] [Abstract][Full Text] [Related]
56. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
57. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
Serratì S; Margheri F; Fibbi G; Di Cara G; Minafra L; Pucci-Minafra I; Liotta F; Annunziato F; Pucci M; Del Rosso M
J Pathol; 2008 Apr; 214(5):545-54. PubMed ID: 18189329
[TBL] [Abstract][Full Text] [Related]
58. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
Hagiwara H; Sato H; Shirai S; Kobayashi S; Fukumoto K; Ishida T; Seki T; Ariga T; Yano T
Life Sci; 2006 Apr; 78(19):2249-54. PubMed ID: 16289236
[TBL] [Abstract][Full Text] [Related]
59. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
60. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
